Pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal anti-SARS-CoV-2 antibody, for COVID-19-related moderate pneumonia: a randomized, double-blind, placebo-controlled, phase IIa study

Benjamin Gaborit, Eric Dailly, Bernard Vanhove, Régis Josien, Karine Lacombe, Vincent Dubee, Virginie Ferre, Sophie Brouard, Florence Ader, Marie-Anne Vibet, Aurélie Le Thuaut, Richard Danger, Laurent Flet, Anne Omnes, Laetitia Berly, Anne Chiffoleau, Alexandra Jobert, Odile Duvaux, François Raffi, POLYCOR trial group
doi: https://doi.org/10.1101/2021.04.15.21255549

Data Availability

The data analysed and presented in this study are available from the corresponding author on reasonable request, providing the request meets local ethical and research governance criteria after publication. Data collected during the study may be processed electronically, in accordance with the requirements of the CNIL (compliance with reference methodology MR001).

Back to top
Posted April 20, 2021.
Download PDF
Data/Code
Email
Pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal anti-SARS-CoV-2 antibody, for COVID-19-related moderate pneumonia: a randomized, double-blind, placebo-controlled, phase IIa study
Benjamin Gaborit, Eric Dailly, Bernard Vanhove, Régis Josien, Karine Lacombe, Vincent Dubee, Virginie Ferre, Sophie Brouard, Florence Ader, Marie-Anne Vibet, Aurélie Le Thuaut, Richard Danger, Laurent Flet, Anne Omnes, Laetitia Berly, Anne Chiffoleau, Alexandra Jobert, Odile Duvaux, François Raffi, POLYCOR trial group
medRxiv 2021.04.15.21255549; doi: https://doi.org/10.1101/2021.04.15.21255549
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area